Metabolic and clinical effects of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370).
D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001663:Bilirubin / Q000097:blood; D001772:Blood Cell Count; D004231:Diuresis / Q000187:drug effects; D005260:Female; D006452:Hemoglobinometry; D006801:Humans; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000188:drug therapy*; D010146:Pain / Q000188:drug therapy; D010653:Phenylbutazone / Q000008:administration & dosage / Q000009:adverse effects; D011720:Pyrazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013729:Terpenes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014527:Uric Acid / Q000097:blood
D000893:Anti-Inflammatory Agents; D011720:Pyrazoles; D013729:Terpenes; D014527:Uric Acid; D010653:Phenylbutazone; D001663:Bilirubin